FDA
approval
· 2016-12-12
FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
Summary
The FDA approved a supplemental application for a fixed-dose combination of pioglitazone and glimepiride (Prasco Laboratories). The indication is for Type 2 dia…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)